VideoHIVEuropean HIV Clinical Forum 2018Novel delivery Systems - What's in the pipeline? | Courtney Fletcher, PharmDView Video
LWLaura WatersMD, FRCPVideoHIVEuropean HIV Clinical Forum 2018Long acting ARV for treatment and prevention - clinical considerations | Laura Waters, MD, FRCPView Video
SWSharon WalmsleyCM, MD, FRCPCVideoHIVEuropean HIV Clinical Forum 2018Integrase Inhibitors in special patient populations | Sharon Walmsley, FRCPC, MD, MSCView Video
PCPedro CahnMD, PhDVideoHIVEuropean HIV Clinical Forum 2018Switch strategies | Pedro Cahn, MD, PhDView Video
JAJose ArribasMDVideoHIVEuropean HIV Clinical Forum 2018Reduced drug regimens - What are the Data? | José Arribas, MDView Video
RPRoger ParedesMD, PhDVideoHIVEuropean HIV Clinical Forum 2018Resistance to Integrase Inhibitors - What Clinicians Need to Know | Roger Paredes, MD, PhDView Video
SlidesetHIVEuropean HIV Clinical Forum 2018Pharmacologic characteristics and delivery options for integrase inhibitors- Courtney Fletcher, PharmDView Slideset
LWLaura WatersMD, FRCPSlidesetHIVEuropean HIV Clinical Forum 2018Long-acting ARV for treatment & prevention: clinical considerations- Laura Waters, MD, FRCPView Slideset
SWSharon WalmsleyCM, MD, FRCPCSlidesetHIVEuropean HIV Clinical Forum 2018Integrase inhibitors in specific populations- Women and those aging with HIV- Sharon Walmsley, FRCPC, MD, MSCView Slideset
SlidesetHIVEuropean HIV Clinical Forum 2018Longer duration of virological suppression and a fully active companion drug ensure a high rate of virological control in HIV-1 infected patients switching to a dual therapy containing integrase inhibitors- Daniele ArmeniaView Slideset
PCPedro CahnMD, PhDSlidesetHIVEuropean HIV Clinical Forum 2018Switching antiretroviral therapy to safer strategies based on intergrase inhibitors- Pedro Cahn, MD, PhDView Slideset
JAJose ArribasMDSlidesetHIVEuropean HIV Clinical Forum 2018Reduced drug regimens- What are the data?- Jose Arribas, MDView Slideset
